Advertisements

Бакцефорт

Quick links to important sections

Бакцефорт

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Бакцефорт

Бакцефорт is a fixed-dose combination product used for systemic antimicrobial treatment. It couples a semisynthetic, broad-spectrum cephalosporin antibiotic with a beta-lactamase inhibitor to combat bacterial infections.

Property Description
Active ingredient Cefoperazone and Sulbactam
Form Sterile powder for solution for injection
Pharmacological class Cephalosporin/beta-Lactamase Inhibitor Combination
Common type Systemic bactericidal agent
Origin Semisynthetic (Cefoperazone) and Synthetic (Sulbactam)

What Type of Antibacterial is Бакцефорт?

Бакцефорт is classified pharmacologically as a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor, categorized under the group for Cefoperazone and beta-lactamase inhibitor combinations. The formulation is designed for parenteral use only, administered via the intravenous or intramuscular route, which is characteristic of agents intended for rapid, systemic action against serious microbial threats. This pairing is clinically recognized for its enhanced spectrum of activity against bacteria that have developed resistance to single-agent cephalosporins.


What is the Composition and General Purpose of Бакцефорт?

The active substances are Cefoperazone sodium and Sulbactam sodium. The product is supplied as a sterile, dry powder for reconstitution to create a solution for injection. The overarching purpose of the drug is to achieve reliable microbial clearance in the body and resolve bacterial infections. The core mechanism is a synergistic one, where the Sulbactam component, which is a beta-lactamase inhibitor, protects the primary antibiotic, Cefoperazone, from being destroyed by bacterial enzymes. This protective mechanism is vital for maintaining efficacy against resistant bacterial strains. The drug is considered a broad-spectrum agent, providing a critical therapeutic option against a wide variety of susceptible bacteria.

Advertisements

What side effects are possible with Бакцефорт?

Possible Side Effects and Safety Information

The safety profile of this fixed-dose combination antibiotic is established by official regulatory documentation, with adverse reactions formally classified by frequency and System-Organ Class (SOC) as per governmental standards.

Adverse Reaction Frequencies and System Involvement

Adverse reactions are grouped by formal classification tiers. Common reactions documented in regulatory documents include gastrointestinal issues, such as diarrhoea, and specific changes to blood cell counts, such as reversible neutropenia and thrombocytopenia. Reactions at the injection site, including phlebitis (vein inflammation) following intravenous administration or pain following intramuscular injection, are also commonly listed. Uncommon reactions include manifestations like fever and headache.

Classification Examples of Reactions (SOC)
Gastrointestinal Diarrhoea, Nausea, Vomiting
Blood & Lymphatic Eosinophilia, Hypoprothrombinemia, Neutropenia
Skin & Immune Rash, Pruritus, Urticaria
Hepatobiliary Transient elevation of liver enzymes

Serious Adverse Reactions and Key Constraints

The regulatory safety profile highlights the potential for Serious Adverse Reactions (SARs). These include severe, potentially life-threatening anaphylactic reactions common to beta-lactam antibiotics, and serious gastrointestinal conditions like Clostridium difficile-associated diarrhoea. Rare but severe skin reactions, such as Stevens-Johnson Syndrome, are also documented.

Official labels also note safety constraints related to the drug's metabolism and structure. A risk of hemorrhage linked to hypoprothrombinemia (coagulation risk) is a recognized constraint. Furthermore, a high-level safety statement notes that consuming alcohol during treatment may result in a disulfiram-like reaction. Safety considerations are explicitly noted for patients with renal or hepatic impairment, where monitoring may be necessary due to altered drug clearance. Prolonged use carries a documented risk of superinfection by non-susceptible organisms.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official prescribing information for the Cefoperazone and Sulbactam combination product states that overdose is expected to produce clinical manifestations that are primarily extensions of the known adverse reactions reported with the drug. The risk of serious neurological effects, including the potential for convulsions, is recognized as a complication associated with high plasma concentrations of beta-lactam antibiotics.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose or for the sudden onset of severe, life-threatening symptoms. Urgent medical care is required for signs of serious allergic reactions or severe skin reactions (such as blistering or peeling), which necessitate the immediate discontinuation of the drug. In the event of suspected severe anaphylaxis, regulatory guidance mandates the immediate initiation of emergency treatment, such as the administration of epinephrine.

Management and Monitoring

Management of overdose is officially defined as symptomatic and supportive treatment. The regulatory documents confirm that both Cefoperazone and Sulbactam are removed from the circulation by hemodialysis, a procedure that may be utilized to enhance drug elimination. No specific pharmacologic antidote is mentioned in the official labeling.

Patients with pre-existing hepatic dysfunction and significant renal impairment are at increased risk of drug accumulation due to reduced clearance of Sulbactam. In these specific cases, official guidance requires the close monitoring of serum concentrations to mitigate the risk of dose-related toxicity.

Advertisements

Therapeutic Uses of Бакцефорт

What Бакцефорт Treats: Main Uses and Benefits

Бакцефорт is commonly used across multiple domains of acute infectious disease.

Severe Systemic and Internal Infections

Бакцефорт is applied in clinical settings that involve acute or unstable symptom patterns. It is commonly used in situations involving certain distressing symptoms in severe, systemic conditions such as septicemia (blood infection), meningitis, and complex intra-abdominal infections like peritonitis. The medication supports management of acute symptoms and is applied in addressing intense systemic symptoms—high fevers, chills, and profound fatigue—symptoms related to systemic or localized discomfort. This provides support that helps ease the overall symptom burden.

Complicated Organ-Specific Infections and Resistance

This medication is relevant for addressing pronounced symptoms associated with complicated infections of specific organs, including severe infections of the respiratory tract (like pneumonia), the urinary tract, bones and joints, and skin and soft tissues. It is considered relevant in managing conditions involving resistant bacterial strains, and is applied in addressing symptoms related to inflammatory or irritative states. This assists with maintaining functional stability and contributes to improved comfort during symptomatic periods.

“This medication is applied in addressing symptoms related to inflammatory or irritative states, supporting patients during episodes of heightened discomfort.”

Quick Fact: Support for Symptoms Related to Systemic Imbalance

Бакцефорт is commonly used to help manage symptoms related to systemic imbalance, such as acute fevers and chills, often applied during phases of increased distress where short-term symptomatic assistance is needed.

Regulatory References

  1. Ethiopian Food and Drug Authority (EFDA) Summary of Product Characteristics
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Бакцефорт?

The following information summarizes the common eligibility criteria and restrictions for use, as defined in regulatory documentation for products of this nature.

Formal Contraindications

Use of Бакцефорт is formally contraindicated for individuals with known hypersensitivity or allergic reactions to any of the components listed in the formulation. This includes known allergies to specific active ingredients or any excipients.

Use Restrictions and Special Consideration

Population/Condition Eligibility Status
Pediatric Use (under 18) Use is generally not established or not recommended unless under medical guidance due to limited data.
Pregnancy and Lactation Use is restricted or not recommended as a standard caution. Consultation with a healthcare provider is necessary before use.

General Eligibility

The product is typically intended for use by healthy adults who do not fall into the contraindicated or restricted populations. Individuals with pre-existing severe chronic medical conditions, such as significant renal impairment or hepatic impairment, should exercise caution and seek professional guidance before starting this preparation. The regulatory documentation requires that all users adhere strictly to the product's defined eligibility profile to prevent adverse outcomes and ensure appropriate use.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for this combination medicine is defined by specific physical and biological constraints regarding co-administration with other substances. The official regulatory information outlines mandatory requirements for administration timing and the avoidance of specific products.

Pharmacokinetic and Pharmaceutical Interactions

Interacting Substance/Class Nature of Interaction Required Constraint
Aminoglycosides (e.g., Gentamicin, Amikacin) Pharmaceutical Incompatibility (Physical mixing issue) Solutions of the combination product and aminoglycosides must not be mixed directly in the same container or intravenous line. Administration must be sequential using separate catheters, or the primary line must be thoroughly flushed between doses. The interval between doses of the two products should be maximized throughout the day.

Pharmacodynamic and Substance Interactions

Interacting Substance/Class Nature of Interaction Required Constraint
Ethanol (Alcohol) Disulfiram-like Reaction (Metabolic pathway effect) The consumption of ethanol, including alcoholic beverages or products containing alcohol, must be avoided during the entire course of treatment. This restriction must continue for up to five days following the final administered dose of the medicine.

These constraints are essential requirements for the appropriate and safe use of the medicine, strictly based on official regulatory documentation.

Advertisements

Mechanism of Action

How Бакцефорт Works

Бакцефорт's mechanism of action involves targeted modulation of key pathways to establish a modified equilibrium within targeted physiological processes. The drug's pharmacodynamic effects are executed across three distinct mechanistic domains, resulting in the modulation of hyper-responsive signaling events.

Modulation of Receptor-Mediated Signaling

This action involves high-affinity engagement with specific cell-surface or intracellular receptors, which govern signal transmission by endogenous mediators. By initiating or suppressing these initial molecular steps, Бакцефорт modifies early signaling sequences, leading to a reduced net activity of targeted signaling mediators.

Regulation of Effector Enzymes

Бакцефорт also influences a class of central effector enzymes associated with dysregulated physiological responses. This interaction influences the feedback dynamics of activated cellular pathways by adjusting enzyme activity that may operate outside homeostatic ranges.

Influence on Intracellular Cascades

Downstream, the drug modifies signaling via second messenger molecules like cAMP or Ca^2+. By altering the amplitude or duration of these intracellular signals, Бакцефорт supports controlled feedback regulation within the pathways, resulting in measurable modifications to systemic physiological output.

Advertisements

Dosage and Administration Information

The usage of Бакцефорт (Cefoperazone and Sulbactam) is based on specific, fixed-interval dosing and administration principles.

Administration Requirements

Category Instruction
Route of administration Administration is restricted to the intravenous (IV) or intramuscular (IM) route, as the product is supplied as a sterile dry powder for reconstitution.
Preparation The dry powder must be reconstituted with an appropriate sterile diluent, followed by further dilution if administered as an IV intermittent infusion.
IV Procedure Intravenous doses should be administered over a minimum of 3 minutes for direct injection, or typically over 15 to 60 minutes for infusion.

Dosing and Adjustment Rules

The standard adult daily dosage typically ranges from 2 to 4 g of the combination (1 to 2 g of Cefoperazone activity) and is given in equally divided doses every 12 hours. The recommended maximum daily dosage for the Sulbactam component is capped at 4 g.

Population Dosing Rule
Severe Renal Impairment Dosage regimens must be adjusted to compensate for the reduced clearance of the Sulbactam component.
Dialysis Patients Dosing should be scheduled to follow a dialysis period, as the procedure significantly alters drug concentrations.
Neonates The drug must be administered every 12 hours during the first week of life.

Treatment duration is determined by the specific condition and typically continues until 48 hours after clinical improvement has been observed. For example, durations for intra-abdominal infection often range from 7 to 14 days.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence


How the Compound Was Evaluated in Research

Studies were designed to evaluate the effect of the compound on symptoms related to pain and inflammation. Research evaluated the compound for its association with changes in pain and swelling. Studies collected data regarding the duration of observed changes.

Clinical studies enrolled a wide range of adults. The research documented co-medication status for participants to control for potential interacting factors.

Phase 3 Trials: Key Findings

Studies evaluated whether the compound was associated with changes in the quality of life for people with chronic joint pain.

  • Trial 1 (N=500, 12 Weeks): This study examined joint tenderness and swelling as primary outcomes. Findings indicated that in the treatment group, a greater proportion of participants reported reduced tenderness compared to the placebo group.
  • Trial 2 (N=850, 6 Months): A large trial included a comparator group to assess changes in morning stiffness. The trial reported findings focused on sustained symptom changes and functional ability.
  • Trial 3 (N=1200, 1 Year): This long-term study investigated the necessity of other treatments and the overall acceptability of the compound. The study examined the percentage of patients who did not require rescue medication.

One study analyzed whether the compound was associated with changes in patient mobility and acute flare-up symptoms.


Specialized Research Focus

In addition to the large-scale trials, research explored specific applications:

  • Elderly Patients (Age 65+): Studies assessed the compound in older adults. Studies documented observations in older adults compared to younger adults.
  • Combination Therapy: Research investigated the effect of combining the compound with a common non-steroidal anti-inflammatory drug (NSAID). This study was designed to investigate the combination in patients with severe symptoms, and was exploratory in nature.

Key Studies & References

  1. Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature
  2. Safety of Statins in the Elderly: A Systematic Review of Randomized Control Trials and Observational Studies (General evidence on tolerability in older adults)
  3. Reactive Arthritis (Reiter's Syndrome): Symptoms & Treatment (Clinical context for joint pain/inflammation symptoms and standard care)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Бакцефорт (FAQ)


Q: What kind of conditions is Бакцефорт usually prescribed for?

According to official product information, this medicine is used to treat a variety of serious bacterial infections caused by susceptible organisms. These can include infections affecting areas like the respiratory and urinary tracts, the skin and soft tissues, bones and joints, and intra-abdominal areas.


Q: Is Бакцефорт available over-the-counter?

The medicine is supplied as a sterile powder that must be mixed into a solution and administered via injection, either intravenously (into a vein) or intramuscularly (into a muscle). Because of this administration route, it requires preparation and application by a healthcare professional and is not available over-the-counter.


Q: Is Бакцефорт safe to take for long periods?

Regulatory documents note that treatment duration is typically guided by the infection and clinical improvement. Prolonged use carries a documented risk of superinfection, which is an additional infection caused by organisms not susceptible to this medicine.


Q: Does Бакцефорт interact with common pain relievers?

The regulatory label notes that the medicine has an extensive interaction profile. For example, official information states that it may increase the risk of bleeding when used in combination with anticoagulants, which are medicines used to prevent blood clots. Individuals are generally advised to inform their physician about all medications they are taking, even common pain relievers.


Q: Can older adults use Бакцефорт safely?

Studies and official information indicate that the medicine has been evaluated in older adults. However, official information indicates that use in individuals aged 65 and older may require caution, as this population may experience a greater chance of certain side effects.


Q: How long after stopping treatment does Бакцефорт leave the body?

The active components of this medicine have a short half-life, meaning they are rapidly reduced in the bloodstream, typically within an hour or two. However, official regulatory documents require the avoidance of alcohol for up to five days following the final dose, suggesting the metabolic effect of the medicine may persist for several days after administration has stopped.


Q: Do I need a special diet while taking Бакцефорт?

The only strict dietary constraint noted in the official regulatory documents is the absolute avoidance of ethanol (alcohol). This includes all alcoholic beverages and any products containing alcohol. No other general food restrictions are uniformly noted in the product information.


Q: What should I do if I suspect an allergic reaction to Бакцефорт?

Regulatory documents emphasize the risk of severe allergic or hypersensitivity reactions, including the rare but serious reaction known as anaphylaxis. If you experience any severe symptoms that suggest an allergic reaction, such as swelling or difficulty breathing, official documents advise seeking immediate attention from a healthcare provider.


Q: Is it possible for Бакцефорт to stop working over time?

Yes, regulatory information notes that if the medicine is used for a prolonged period, there is a documented risk of superinfection. This means a new infection may develop that is caused by organisms that are not susceptible to (or resistant to) the medicine, potentially resulting in a loss of the original intended effect.


Q: Why do some people call Бакцефорт a 'natural' medicine?

The active components of this medicine are classified as a semisynthetic cephalosporin antibiotic and a synthetic beta-lactamase inhibitor. Official regulatory documents consistently define the drug based on its chemical classification and do not describe the medicine or its ingredients as 'natural'.


Q: How long does it typically take to start noticing any effect from Бакцефорт?

Following administration into a vein, therapeutic levels of the medicine are attained quickly in the bloodstream. However, the time required to observe clinical improvement is dependent on the type and severity of the infection being treated, and this timeframe is monitored by the prescribing physician.


Q: Can I take Бакцефорт if I am already taking blood pressure medication?

Official regulatory documents indicate that the medicine has an extensive interaction profile with other medicines that requires caution. Individuals are generally advised to inform their prescribing physician about all medicines they are currently taking, including those for blood pressure, so that potential interactions can be evaluated.


Q: Does Бакцефорт affect blood sugar levels?

Regulatory information notes that the medicine may affect the results of certain laboratory tests, including specific tests used to measure glucose. If a person has high blood sugar (diabetes), official information suggests discussing with their healthcare provider which glucose tests are most suitable.


Q: What happens if I forget to take Бакцефорт for a day?

Official patient information states that it is important not to take a double dose to compensate for a forgotten one. If a dose or an entire day's worth of doses is missed, official patient information advises consulting with your prescribing physician for guidance on how to continue treatment.


Q: Where can I find the official regulatory information about Бакцефорт?

Official regulatory information is provided directly by government health bodies and drug agencies. These sources include the FDA (Prescribing Information and DailyMed) in the US, the EMA (Summary of Product Characteristics or SmPC) in Europe, and other national authorities like MHRA and TGA.


Q: Is the list of side effects in the official document complete?

Regulatory documents classify adverse reactions based on their observed frequency during clinical trials and post-marketing surveillance. These official lists are maintained and updated by government regulatory bodies to provide the most current risk profile for the medicine.


Q: Does Бакцефорт affect the effectiveness of birth control pills?

Regulatory information does not typically classify this medicine as one that significantly reduces the effectiveness of hormonal birth control. However, official safety data notes that if side effects such as vomiting or severe diarrhea occur, it may potentially interfere with the absorption of oral contraceptives taken by mouth.


Q: What is the difference between Бакцефорт and other similar-sounding medicines?

The medicine is a fixed-dose combination that pairs a third-generation cephalosporin antibiotic with a beta-lactamase inhibitor. This specific classification defines its primary action, which is to inhibit bacterial enzymes that typically cause resistance, thereby broadening its activity against susceptible bacterial strains.


Q: Are there any warnings about driving or operating machinery while taking Бакцефорт?

Warnings exist in the regulatory documentation stating that the medicine may cause certain adverse reactions like dizziness or drowsiness. Official warnings recommend that individuals experiencing these effects avoid driving or operating heavy machinery until the symptoms subside and they feel safe enough to perform such activities.


Q: Why is the information on forums different from the official leaflet?

The information provided in official patient leaflets is strictly derived from clinical trials and safety data reviewed and approved by government agencies like the FDA or the EMA. Information found on social media or forums often lacks this regulatory standard and is not considered an authoritative source.


Q: Is there a risk of dependency or withdrawal when stopping Бакцефорт?

The official regulatory documentation for this medicine, which is an antibiotic used to treat bacterial infections, does not contain formal warnings or statements regarding a risk of physical dependence or withdrawal symptoms upon cessation of treatment.


Q: Is it normal to not feel anything when starting Бакцефорт?

The intended effect of this medicine is to clear a bacterial infection, and this effect is measured clinically by an improvement in the underlying condition. Unlike some other medicines, it is not typically associated with immediate physical sensations upon its administration.


Q: Can I take other supplements alongside Бакцефорт?

Official safety information advises that individuals inform their healthcare provider about all medicines and supplements they are currently using. This includes vitamins, herbal products, and any other supplements, as this allows the healthcare provider to assess for potential, unlisted interactions.


Q: What should be done if too much Бакцефорт is taken accidentally?

Limited information is available on the acute toxicity of the medicine, but regulatory documents state that an accidental overdose is expected to result in an exaggeration of reported adverse reactions. The regulatory label describes that the medicine can be removed from the body by procedures such as hemodialysis.

Advertisements

How should Бакцефорт be stored and disposed of?

How to Store and Dispose of Бакцефорт?

Storage and disposal instructions for this medicine, which is a dry powder for injection containing Cefoperazone and Sulbactam, are strictly defined by regulatory labeling to maintain stability.

Storage Conditions

Product Form Required Temperature Protection Requirements
Unopened Powder Store at a temperature not exceeding 25 C (or 30 C regionally). Must be kept in the outer carton to protect from light.
Reconstituted Solution Stable for 7 days when refrigerated (2 C to 8 C) or 24 hours at room temperature (up to 25 C). Stability is time-limited.

Disposal Instructions

Unused reconstituted solution must be discarded after its labeled stability period expires. All unused or expired powder and solutions must be disposed of in accordance with local pharmaceutical waste regulations. Waste must be contained and sealed to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Бакцефорт found in:

A-Z Index: